English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Previous studies have reported that 99mTc-3PRGD2 is an excellent tumor imaging agent that showed a good correlation with integrin αvβ3, a main factor of tumor-induced angiogenesis. In this study, we investigated the biometabolic distribution characteristics of 99mTc-3PRGD2 with a continuous dynamic acquisition mode to explore the potential value of 99mTc-3PRGD2 in monitoring chemotherapeutic effects in VX2 tumor models. Eighteen rabbits with 27 implanted VX2 squamous cell tumors were randomly divided into a nontreated control group (NTG, n = 8; 12 tumors) and a treatment group (TG, n = 10; 15 tumors). 99mTc-3PRGD2 imaging was performed prior to cisplatin injection and repeated on days 0, 1, 7, and 14 postinjection. Continuous dynamic scanning up to 30 minutes; static imaging at 0.5 hours, 1 hour, and 3 hours; and single-photon emission computed tomography/computed tomography (SPECT/CT)-integrated imaging at 3 hours post-99mTc-3PRGD2 injection were performed. The peak time (time to reach peak in dynamic curve), tumor to normal (T/N) ratios, and their change rates relative to pretherapy were calculated. Autoradiography, hematoxylin-eosin (H&amp;E) staining, and CD31 and integrin αv immunohistochemical staining were examined. VX2 tumors were clearly visualized at 3 hours post-99mTc-3PRGD2 injection. Tumors in the TG shrank significantly on day 7 after cisplatin administration (p &lt; .05). The half-life (t1/2) of the radiotracer in heart, liver, and tumor in the NTG were 3.43 ± 0.94 minutes, 13.41 ± 9.17 minutes, and 70.83 ± 33.37 minutes, respectively. The peak time was delayed in the TG immediately and continuously after cisplatin administration compared to the peak time in the NTG. The T/N values and their change rates decreased significantly in the TG compared to the NTG after therapy (p &lt; .05). The immunostained areas were significantly decreased in the TG (p &lt; .05) compared to the NTG. 99mTc-3PRGD2 was an excellent imaging agent for demonstrating tumor angiogenesis. The peak time, T/N values, and their change rates were sensitive parameters to monitor early chemotherapeutic effects. Due to the specific target mechanism and the cost-effective value of 99mTc-3PRGD2, 99mTc-3PRGD2 SPECT imaging may have potential in detecting the therapeutic effects of anticancer therapy.

Biometabolic Distribution of 99m Tc-3PRGD2 and its Potential Value in Monitoring Chemotherapeutic Effects

Biometabolic Distribution of ^99m Tc-3PRGD2 and its Potential Value in Monitoring Chemotherapeutic Effects